Carboplatin (C) and docetaxel (D) in the second-line treatment of non-small cell lung cancer (NSCLC) patients pretreated with platinum-based regimens. A Phase II trial

被引：0
|
作者：
Numico, G
Buffoni, L
Dongiovanni, V
Schena, M
Fissore, C
Fea, E
Occelli, M
Colantonio, I
Merlano, M
Bertetto, O
机构：
[1] S Croce Gen Hosp, Cuneo, Italy
[2] S Giovanni Hosp, Turin, Italy
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81035-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S260 / S260
页数：1
相关论文
共 50 条
  • [41] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [42] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [43] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [44] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, GV
    Selvaggi, G
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 23 - 26
  • [46] Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial
    Gridelli, C
    Perrone, F
    Gallo, C
    Rossi, A
    Barletta, E
    Barzelloni, ML
    Creazzola, S
    Gatani, T
    Fiore, F
    Guida, C
    Scognamiglio, F
    ANTICANCER RESEARCH, 1999, 19 (5C) : 4535 - 4538
  • [47] A phase II trial of biweekly docetaxel combined with carboplatin for patients with advanced non-small cell lung cancer
    Ishimoto, O
    Sugawara, S
    Inoue, A
    Ishida, T
    Koinumaru, S
    Hasegawa, Y
    Suzuki, T
    Miki, H
    Saijo, Y
    Nukiwa, T
    LUNG CANCER, 2005, 49 : S391 - S391
  • [48] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [49] Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
    Watanabe, Naohiro
    Niho, Seiji
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Ohmatsu, Hironobu
    Goto, Koichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 69 - 74
  • [50] Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
    Naohiro Watanabe
    Seiji Niho
    Keisuke Kirita
    Shigeki Umemura
    Shingo Matsumoto
    Kiyotaka Yoh
    Hironobu Ohmatsu
    Koichi Goto
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 69 - 74
12345